Division of Cancer Interdisciplinary Research and Development Field
Introduction
We work on bioinformatics and chemoinformatics to analyze various biomedical bigdata. Recent developments in biotechnology have contributed to the increase in the amounts of high-throughput data in the genome, transcriptome, proteome, interactome, phenome and diseasome. At the same time, the high-throughput screening of large-scale chemical compound libraries with various biological assays is enabling us to explore the chemical space of possible compounds. These big data can be useful resources for medical science and drug discovery. Artificial intelligence and machine learning methods play key roles in the big data analysis. We develop novel machine learning methods for various applications in medical science and drug discovery such as therapeutic target identification, biomarker identification, virtual compound screening, and drug molecular structure design.
Research topics
https://yamanishi.cs.i.nagoya-u.ac.jp
Members
Yoshihiro Yamanishi
Research fields
AI-driven drug discovery, Bioinformatics, Chemoinformatics
Message
I conduct research on AI-driven drug discovery to efficiently develop medicines by analyzing various big data related to cancer, genes, and proteins using artificial intelligence. My goal is to deliver therapeutic drugs quickly, affordably, and reliably to patients suffering from cancer.
Yohey Kamijo
Research fields
Identification of cancer therapeutic targets and biomarkers
Message
I conduct research on cancer initiation, progression, therapeutic targets, cancer cell senescence, and prognosis prediction by utilizing genetic and protein data. I am committed to contributing to the well-being of cancer patients through the application of information science.
Futaba Itazu
Research fields
Regulation of cancer and senescence, induction of rejuvenation
Message
I conduct research to elucidate the mechanisms of senescence regulation and predict compounds that rejuvenate cells, using big data derived from cancer cells. From the perspective of information science, I aim to develop new therapies that contribute to cancer prevention, treatment, and the suppression of recurrence.
